Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 56

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 56
---
38

TABLE OF CONTENTS

Cash Compensation Under this policy, we pay each of our non-executive directors annual fees for service on our board of directors and committees of our board of directors, which amounts may be amended from time to time by the board of directors. We also reimburse non-executive directors for all reasonable and properly documented expenses related to attendance at board and committee meetings. U.S. non-executive directors are also provided with tax-equalization benefits. Non-executive directors do not receive any pension benefits or cash in lieu thereof. Non-executive directors are eligible to receive cash compensation as follows:

|                                                                                                                    |     |   Annual Fee 
 Retainer ($) |
| Annual fee for board of director chairperson (in addition to annual director service retainer)                     |     |       35,000 |
| Annual director service retainer                                                                                   |     |       50,000 |
| Additional fee for audit committee chair (in lieu of annual member service retainer)                               |     |       20,000 |
| Additional fee for audit committee member                                                                          |     |       10,000 |
| Additional fee for nominating and corporate governance committee chair (in lieu of annual member service retainer) |     |       10,000 |
| Additional fee for nominating and corporate governance committee member                                            |     |        5,000 |
| Additional fee for remuneration committee chair (in lieu of annual member service retainer)                        |     |       15,000 |
| Additional fee for remuneration committee member                                                                   |     |        7,500 |

Equity Compensation In addition to cash compensation, each non-executive director is eligible to participate in the Non-Employee Sub-Plan to the Immunocore Holdings plc 2021 Equity Incentive Plan (“2021 EIP”). All share options granted under our non-executive director remuneration policy will be non-statutory stock options, with an exercise price per share equal to 100% of the fair market value (as such term is defined in our 2021 EIP) of the underlying ordinary shares on the date of grant, and a term of ten years from the date of grant, subject to earlier termination in connection with a “Termination of Service” (as such term is defined in our 2021 EIP). Initial Grant Each eligible director who is first elected or appointed to our board of directors automatically, and without further action by our board of directors or the remuneration committee, upon the